# Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention.

> **NCT06754540** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 51 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Relapse

## Interventions

- **DRUG:** Azacitidine (AZA)

## Key facts

- **NCT ID:** NCT06754540
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-16
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06754540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06754540, "Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06754540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*